206.14MMarket Cap0.12P/E (TTM)
14.440High14.050Low76.79KVolume14.230Open14.220Pre Close1.09MTurnover1.01%Turnover Ratio0.12P/E (Static)14.48MShares18.95052wk High1.54P/B108.55MFloat Cap10.80052wk Low--Dividend TTM7.62MShs Float18.950Historical High--Div YieldTTM2.74%Amplitude10.800Historical Low14.186Avg Price1Lot Size
Inhibrx Biosciences Stock Forum
Inhibrx Cancer Drug Shows Complete Response as Company Posts $1.7B Annual Profit
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
8. With regards t...
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
8. With regards ...
Inhibrx Biosciences Announces Preliminary Data from the Phase 1 Trial of ozekibart (INBRX-109) for the Treatment of Colorectal Cancer
Tuesday, 21st January at 5:01 pm
SAN DIEGO, Jan. 21, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (NASDAQ: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapeutics for oncology and rare diseases, today announced preliminary efficacy and safety data from the Phase 1 trial...
No comment yet